Compare McKesson Corporation (MCK) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Toyota Motor Corp — how do they compare? McKesson Corporation trades at $829.95 (market cap $97.35B), while Toyota Motor Corp trades at $180.78 (market cap $212.22B). The key difference: Toyota Motor Corp is far larger — about 2.2× McKesson Corporation's market cap, and Toyota Motor Corp pays the higher dividend (3.51%). Which is the better fit depends on your goals.
| MCK | TM | |
|---|---|---|
Market Cap | $97.35B | $212.22B |
Sector | Health | Consumer Cyclical |
52-Week High | $995.69 | $248.29 |
52-Week Low | $659.01 | $166.50 |
Enterprise Value | $101.98B | $376.42B |
Dividend Yield | 0.39% | 3.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Toyota Motor (TM) trades at $178.53, up 0.52% with neutral technical signals. The stock shows strong fundamentals with a low P/E of 9.73 and consistent earnings beats, including Q1 2026 EPS of $4.00 versus $3.11 expected. Recent news highlights a $3.6 billion Texas plant expansion announced July 6, 2026 (Reuters), signaling growth commitment. Cash flow trends show a 2025 dip but project recovery in 2026 with operating cash flow of $5.47 trillion.
Outlook is cautiously positive given undervaluation and hybrid vehicle demand, but risks include rising debt-to-asset ratios (41.29% in 2025) and margin pressure. Analyst consensus is mixed with 37.5% buy ratings, suggesting potential upside if execution aligns with expansion plans.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
